Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Exploring the Role of Brexpiprazole in Alzheimer Dementia Agitation
How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?
2 Commerce Drive Cranbury, NJ 08512